贝伐珠单抗联合mFOLFOX6方案治疗晚期结肠癌的临床效果及对血清CEA的影响  

Clinical effect of bevacizumab combined with mFOLFOX6 in treatment of advanced colon cancer and its effect to serum CEA

作　　者：陈志勇[1] 陈珍[1] 丘金花 郑秋香[1] 黄文金[1] CHEN Zhiyong CHEN Zhen QIU Jinhua ZHENG Qiuxiang HUANG Wenjin(Department of Oneology, Longyan First Hospital affiliated to Fujian Medical University, Longyan364000, Chin)

机构地区：[1]福建医科大学附属龙岩第一医院肿瘤科,福建龙岩364000

出　　处：《中国医药科学》2017年第10期11-14,共4页China Medicine And Pharmacy

摘　　要：目的探讨贝伐珠单抗与m FOLFOX6方案联合治疗晚期结肠癌的临床价值。方法选取2013年1月~2016年1月我院收治的晚期结肠癌患者58例为研究对象,经随机数字表法分为观察组与对照组,每组29例,对照组给予m FOLFOX6化疗方案治疗,观察组在对照组基础上加用贝伐珠单抗治疗,观察两组治疗效果、不良反应发生情况、无进展存活时间(PFS)及血清癌胚抗原(CEA)水平变化。结果观察组治疗总有效率为51.72%,同对照组24.14%比较,显著较高,差异有统计学意义(P<0.05);两组患者神经毒性、高血压、白细胞减少、胃肠道反应、蛋白尿、出血、肝功能异常发生率,差异无统计学意义(P>0.05);观察组PFS时间同对照组比较,显著较长,差异有统计学意义(P<0.05);治疗前两组血清CEA水平差异无统计学意义(P>0.05),治疗后均有下降,观察组治疗后血清CEA水平明显较对照组低,差异有统计学意义(P<0.05)。结论晚期结肠癌患者接受贝伐珠单抗联合m FOLFOX6方案治疗,近远期效果确切,可明显降低血清肿瘤标志物浓度,且具有较高安全性,值得推广。Objective To explore the clinical value of bevacizumab combined with mFOLFOX6 in treatment of advanced colon cancer. Methods 58 cases of advanced colon cancer cured in our hospital from January 2013 to January 2016 were selected as the study objects. According to random digital table method, they were divided into observation group and control group with 29 cases in each. Patients in control group were treated with mFOLFOX6 chemotherapy regimen, and patients in observation group were treated with bevacizumab on the basis of mFOLFOX6 chemotherapy regimen. The therapeutic effect, adverse reaction, Progression-Free-Survival（PFS） and Carcino- Embryonic Antigen（CEA） levels of the two groups were observed. Results The total effective rate of the observation group was 51.72%, which was significantly higher than that of the control group with 24.14%, and the difference had statistical signifieance（P 〈 0.05）. There was no significant difference between the two groups in the incidence of neurotoxicity, hypertension, reduction of white blood cells, gastrointestinal reaction, proteinuria, hemorrhage and abnormal liver function（P ~ 0.05）. The PFS time of the observation group was significantly longer than that of the control group, and the difference was statistically significant（P 〈 0.05）. There was no significant difference in serum CEA level between the two groups before treatment（P 〈 0.05）. After treatment, both the two group were decreases, the levels of serum CEA in the observation group were significantly lower than those in the control group, and the difference was statistically significant（P 〈 0.05）. Conclusion The short-and long-term therapeutic effect of bevaeizumab combined with mFOLFOX6 in treatment of advanced colon cancer is exact. It can significantly reduce the concentration of serum tumor markers. And it has high security. It is worth promoting.

关 键 词：晚期结肠癌 化疗 贝伐珠单抗 无进展存活时间 癌胚抗原 

分 类 号：R735.3[医药卫生—肿瘤]